Jonathan Chou, MD, PhD

Asst. Professor In Residence
+1 415 476-1314
Research Overview: 

Our research group is interested in cancer biology and translational oncology. Current research focuses on (1) understanding the molecular drivers of genitourinary cancers, including CDK12 mutations in prostate cancer; (2) investigating the mechanisms that contribute to disease progression, drug resistance and metastasis, including the role of the tumor immune microenvironment; and (3) developing novel surface-targeting therapies, including CAR T cells, bispecific immune cell engagers, antibody drug conjugates and radioimmunotherapies.

Our lab is part of the UCSF Prostate Cancer and Bladder Cancer Programs, the Division of Hematology/Oncology, and the UCSF Helen Diller Family Comprehensive Cancer Center. We utilize cancer cell biology, immunology, CRISPR screening, mouse modeling and genomic approaches, and aim to translate discoveries from the lab into the clinic.

We work collaboratively with basic scientists, radiologists, chemists, computational biologists, pathologists, urologic surgical oncologists, radiation oncologists and medical oncologists. We are excited to share our research with you!

Primary Thematic Area: 
Cancer Biology & Cell Signaling
Secondary Thematic Area: 
Research Summary: 
Mechanisms underlying transcriptional dysregulation, DNA damage responses, inflammation and resistance. Design theranostics targeting the cancer surface proteome and define synthetic lethal interactions.


Featured Publications: 

Immunotherapeutic targeting and PET imaging of DLL3 in small cell neuroendocrine prostate cancer.

Cancer research

Chou J, Egusa EA, Wang S, Badura ML, Lee F, Bidkar AP, Zhu J, Shenoy T, Trepka K, Robinson TM, Steri V, Huang J, Wang Y, Small EJ, Chan E, Stohr BA, Ashworth A, Delafontaine B, Rottey S, Cooke KS, Hashemi Sadraei N, Yu B, Salvati M, Bailis JM, Feng FY, Flavell RR, Aggarwal R

Theranostic targeting of CUB domain containing protein 1 (CDCP1) in multiple subtypes of bladder cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research

Chopra S, Trepka K, Sakhamuri S, Carretero-González A, Zhu J, Egusa E, Zhou J, Leung K, Zhao N, Hooshdaran N, Feng FY, Wells JA, Chou J, Evans MJ

Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin.

Clinical cancer research : an official journal of the American Association for Cancer Research

Chu CE, Sj?str?m M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J

Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.

Cancer discovery

Chou J, Quigley DA, Robinson TM, Feng FY, Ashworth A

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer.

European urology

Reimers MA, Yip SM, Zhang L, Cieslik M, Dhawan M, Montgomery B, Wyatt AW, Chi KN, Small EJ, Chinnaiyan AM, Alva AS, Feng FY, Chou J

Remodelling the extracellular matrix in development and disease.

Nature reviews. Molecular cell biology

Bonnans C, Chou J, Werb Z

GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression.

Nature cell biology

Chou J, Lin JH, Brenot A, Kim JW, Provot S, Werb Z